Father's alcohol consumption can affect fetal development; Heng ruiang dansetron mouth lysis membrane is about to be approved

Introduction: Father's drinking alcohol will affect fetal development; the first! Hengrui on Dansiqiong mouth-soluble membrane is about to be approved; Yusen Jianheng Biomedical completed a round of financing of 200 million yuan; Kaiskaidi received nearly 100 million yuan in financing to accelerate the research and development of innovative drugs for nuclear receptors and GPCRs... Bio-Discovery works with you to follow the "medicine" smell and explore the value of biotechnology!

01

Father alcohol consumption can affect fetal development

A new study suggests that epigenetic factors in father exposure to alcohol can manifest themselves in the placenta. The researchers' data showed that in mice, fathers exposed to alcohol had offspring with fetal growth restriction, placenta enlargement, and placenta reduction. The researchers say the placenta becomes overgrown as they try to compensate for the less efficient delivery of nutrients to the fetus as they try to compensate. These results do not explicitly illustrate how alcohol consumption in human males before conception affects fetal development, but they at least illustrate that this is a matter of discussion that needs to be further explored.

02

First! Heng Rui on Dansetron oral lysis membrane is about to be approved

Recently, the listing application of Hengrui Pharmaceutical's class 3 generic drug Ondansetron oral soluble membrane was changed to "under approval" in NMPA, and if it can be successfully approved, it will become the first imitation of this variety. Ondansetron is a selective 5-HT3 receptor antagonist that is clinically mainly used as an antiemetic for nausea and vomiting caused by cytotoxic drug chemotherapy and radiation therapy, and can also be used to prevent and treat nausea and vomiting after surgery. Moreover, ondansetron can also promote gastric emptying under antiemetic doses, help reduce nausea symptoms, have anxiolytic and calming effects on the central nervous system, and inhibit the excitement of the vomiting center.

03

Yusen Jianheng Biopharma completed a round of financing of 200 million yuan

On February 8, Yusen Jianheng Biopharma announced that the company has recently completed more than 200 million yuan A round of financing, this round of financing is led by Shenzhen Sharing Investment, Zhang Jiang Haoheng and Yingke Capital followed, and the original shareholders continue to participate in this round of investment. The funds raised will be used to carry out and accelerate the clinical trials of core research projects UA007 and UA021 in China and overseas, the development of small molecule drugs with multiple new targets, and the research and development of specific dual-antibody innovative drugs.

04

Kath Cady received nearly 100 million more financing to accelerate the nuclear receptor

Innovative drug development with GPCR

Recently, Kaiskaidi announced the completion of nearly 100 million yuan Pre-A+ round of financing, which is the second time that Kaiskaidi has obtained a new round of financing after completing the Pre-A round of financing in October 2020. This round of financing is led by the fund of the new investor West Lake Innovation (Hangzhou) Equity Investment Co., Ltd., and the old shareholders such as Gaorong Capital, Fuhui Venture Capital and Gemdale Capital continue to follow suit. The company will use the funds obtained from this round of financing to accelerate the follow-up research and development of many of the company's core products.